TScan Therapeutics, Inc.
TCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001783328
No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in TScan Therapeutics, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 26
- +2 vs. Q2 2022
- Shares held
- 9.51M
- −173.8K (−1.8%) vs. Q2 2022
- Total value
- $29.0M
- −$1.45M (−4.7%) vs. Q2 2022
- New holders
- 3
- 6 more added
- Sold out
- 1
- 6 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TCRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 60 | $35.1M |
| Q1 2026 | 60 | $32.8M |
| Q4 2025 | 61 | $30.7M |
| Q3 2025 | 73 | $62.9M |
| Q2 2025 | 81 | $51.8M |
| Q1 2025 | 92 | $55.4M |
| Q4 2024 | 89 | $126.2M |
| Q3 2024 | 89 | $208.3M |
| Q2 2024 | 81 | $242.6M |
| Q1 2024 | 66 | $272.3M |
| Q4 2023 | 54 | $186.1M |
| Q3 2023 | 32 | $73.2M |
| Q2 2023 | 28 | $69.9M |
| Q1 2023 | 28 | $20.3M |
| Q4 2022 | 28 | $14.8M |
| Q3 2022 | 26 | $29.0M |
| Q2 2022 | 24 | $30.4M |
| Q1 2022 | 25 | $26.3M |
| Q4 2021 | 29 | $44.4M |
| Q3 2021 | 27 | $83.5M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding TScan Therapeutics, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 72 | $0 | 0.00% | +26+56.5% | Added |
| Royal Bank of Canada | 184 | $1.00K | 0.00% | +184 | New |
| Atlas Capital Advisors LLC | 896 | $2.73K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 3,441 | $11.0K | 0.00% | +2,293+199.7% | Added |
| Tower Research Capital LLC (TRC) | 6,043 | $18.0K | 0.00% | −2,984−33.1% | Reduced |
| Prudential Financial Inc | 11,000 | $34.0K | 0.00% | +11,000 | New |
| State Street Corp | 13,400 | $41.0K | 0.00% | 00.0% | Unchanged |
| Cannell Capital LLC | 14,666 | $45.0K | 0.01% | +11,012+301.4% | Added |
| LPL Financial LLC | 15,000 | $46.0K | 0.00% | −1,000−6.3% | Reduced |
| Privium Fund Management (UK) Ltd | 15,825 | $48.0K | 0.06% | +15,825 | New |
| Marquette Asset Management, LLC | 28,895 | $88.0K | 0.03% | 00.0% | Unchanged |
| DC Investments Management, LLC | 35,563 | $110.0K | 0.25% | 00.0% | Unchanged |
| Morgan Stanley | 64,570 | $197.0K | 0.00% | +7,481+13.1% | Added |
| Woodline Partners LP | 66,601 | $203.0K | 0.00% | −65,716−49.7% | Reduced |
| Geode Capital Management, LLC | 100,669 | $307.0K | 0.00% | +66,568+195.2% | Added |
| Bridgeway Capital Management, LLC | 115,000 | $351.0K | 0.01% | 00.0% | Unchanged |
| Newtyn Management, LLC | 200,000 | $610.0K | 0.13% | −48,611−19.6% | Reduced |
| Tekla Capital Management LLC | 200,000 | $610.0K | 0.02% | 00.0% | Unchanged |
| Vanguard Group Inc | 257,416 | $785.0K | 0.00% | +31,352+13.9% | Added |
| Adage Capital Partners GP, L.L.C. | 550,000 | $1.68M | 0.00% | 00.0% | Unchanged |
| Tang Capital Management LLC | 557,915 | $1.70M | 0.21% | −189,885−25.4% | Reduced |
| DC Funds, LP | 630,000 | $1.92M | 28.97% | 00.0% | Unchanged |
| Alphabet Inc. | 1,077,080 | $3.29M | 0.17% | 00.0% | Unchanged |
| Deer Management Co. LLC | 1,245,505 | $3.80M | 0.27% | 00.0% | Unchanged |
| BlackRock Inc. | 1,513,815 | $4.62M | 0.00% | −1,149−0.1% | Reduced |
| Baker Bros. Advisors LP | 2,784,792 | $8.49M | 0.06% | 00.0% | Unchanged |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −10,176−100.0% | Sold out |